Clinical Trials


Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)

This study has been completed
Bristol-Myers Squibb

Information provided by (Responsible Party)
Bristol-Myers Squibb Identifier

First received: November 2, 1999
Last updated: April 13, 2011
Last Verified: April 2011
History of Changes


Didanosine is an effective anti-HIV drug, but it can cause stomach upset. This study tests a new form of didanosine, ddI EC, a coated pill that passes through the stomach more easily and hopefully will prevent stomach upset. The purpose of this study is to compare the effectiveness of ddI EC versus the standard form of ddI. Both forms of ddI will be given with stavudine (d4T) plus nelfinavir (NLF).

Condition Intervention Phase
HIV Infections

Drug : Nelfinavir mesylate
Drug : Stavudine
Drug : Didanosine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of HIV RNA Suppression Produced by Triple Regimens Containing Either Didanosine Enteric Coated or Didanosine Formulations Each Administered Once Daily

Further study details as provided by Bristol-Myers Squibb:

Enrollment: 120
Study Start Date: March 1999
Study Completion Date: March 1999
Primary Completion Date: March 1999 (Final data collection date for primary outcome measure)

Detailed Description:

Patients are randomized to 1 of 2 open-label treatment groups. Group 1 receives ddI EC plus d4T plus NLF for 48 weeks. Group 2 receives ddI plus d4T plus NLF for 48 weeks. Both forms of ddI are administered orally once daily. Antiviral activity is determined by the magnitude and the duration of reduction of plasma HIV RNA from baseline through Week 24.



Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria
You may be eligible for this study if you:

  • Are HIV-positive.
  • Are at least 18 years old.
  • Have a viral load of at least 5,000 copies/ml and a CD4 count of at least 100 cells/mm3.

  • Exclusion Criteria
    You will not be eligible for this study if you:
  • Have received more than 4 weeks of treatment with nucleoside anti-HIV medications (NRTIs), or more than 1 week with protease inhibitors. (All anti-HIV treatments other than study medications must be stopped at least 14 days prior to study entry.)
  • Have severe diarrhea.
  • Are pregnant or breast-feeding.
  • Have a history of pancreatic disease or any other serious condition.
  • Have hepatitis within 30 days prior to study entry.
  • Cannot take medications by mouth.
  • Have received certain medications.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00002224


United States, Alabama
Sorra Research Ctr / Med Forum
Birmingham, Alabama, United States, 35203
United States, California
AIDS Healthcare Foundation
Los Angeles, California, United States, 900276069
Robert Scott MD
Oakland, California, United States, 94609
United States, Colorado
Beacon Clinic / Boulder Community Hosp
Boulder, Colorado, United States, 80304
United States, Florida
Community Health Care
Fort Lauderdale, Florida, United States, 33306
Immunity Care and Research Inc
Fort Lauderdale, Florida, United States, 33311
HIV Clinical Research Ctr
Fort Lauderdale, Florida, United States, 33316
South Shore Hosp
Miami, Florida, United States, 33139
Saint Josephs Comprehensive Research Institute
Tampa, Florida, United States, 33607
United States, Georgia
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States, 303081962
United States, Illinois
Chicago Ctr for Clinical Research
Chicago, Illinois, United States, 60610
United States, Kansas
Univ of Kansas School of Medicine
Wichita, Kansas, United States, 672143124
United States, Nebraska
Univ of Nebraska Med Ctr
Omaha, Nebraska, United States, 681985400
United States, Nevada
Clinical Studies of Las Vegas
Las Vegas, Nevada, United States, 89128
United States, New York
Anderson Clinical Research Inc
Rego Park, New York, United States, 11374
United States, Pennsylvania
Anderson Clinical Research Inc
Reading, Pennsylvania, United States, 19604
United States, South Carolina
Coastal Carolina Research Ctr
Mount Pleasant, South Carolina, United States, 29464
United States, Texas
Oak Lawn Physicians Group
Dallas, Texas, United States, 75219
Univ of Texas Southwestern Med Ctr of Dallas
Dallas, Texas, United States, 752359103
Nicholaos Bellos
Dallas, Texas, United States, 75246
Houston Clinical Research Network / Div of Montrose Clinic
Houston, Texas, United States, 77006
United States, Washington
Swedish Med Ctr
Seattle, Washington, United States, 98122
Clinique Medicale du Quartier Latin
Montreal, Quebec, Canada
Clinique Medicale L'Actuele
Montreal, Quebec, Canada

Sponsors and Collaborators

Bristol-Myers Squibb
More Information

More Information

Responsible Party: Bristol-Myers Squibb Identifier: NCT00002224   History of Changes  
Other Study ID Numbers: 039G  
Study First Received: November 2, 1999  
Last Updated: April 13, 2011  

Keywords provided by Bristol-Myers Squibb:

Drug Therapy, Combination
Drug Administration Schedule
HIV Protease Inhibitors
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Viral Load

Additional relevant MeSH terms:
HIV Infections
Didanosine processed this data on February 13, 2020
This information is provided by